-
Big Pharma. Bigger Pharma. Big Honkin' Pharma
-
The Pfizer-Allergan merger raises red flags on two fronts: one, that the $160 billion deal means less competition and higher drug prices (as if they're not high enough), and two, it's another inversion deal, with Pfizer buying Allergan and then having Allergan be the survivor, then renaming Allergan "Pfizer" but leaving the headquarters overseas... and thus not an American company for tax purposes. So, higher prices AND lower tax revenue. Let's face it, you can't blame them for doing it. But this isn't going to be good for the general public. (Los Angeles Times)
Have an opinion? Add your comment below.